Cencora, Inc. (NYSE:COR) Receives $271.20 Average PT from Analysts

Shares of Cencora, Inc. (NYSE:COR) have earned a consensus rating of “Moderate Buy” from the eleven analysts that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $271.20.

COR has been the subject of a number of recent research reports. JPMorgan Chase & Co. upped their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. Wells Fargo & Company upped their price objective on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research note on Thursday, August 1st. Bank of America reissued a “neutral” rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. UBS Group raised their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Barclays boosted their price objective on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of Cencora stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. The trade was a 7.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 93,018 shares of company stock worth $22,478,942 in the last 90 days. Corporate insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kingswood Wealth Advisors LLC bought a new position in Cencora in the second quarter worth approximately $655,000. Czech National Bank lifted its holdings in shares of Cencora by 8.3% in the 2nd quarter. Czech National Bank now owns 31,546 shares of the company’s stock worth $7,107,000 after purchasing an additional 2,414 shares in the last quarter. Mackenzie Financial Corp grew its position in Cencora by 9.9% in the 2nd quarter. Mackenzie Financial Corp now owns 81,001 shares of the company’s stock valued at $18,250,000 after purchasing an additional 7,266 shares during the period. Portfolio Design Labs LLC acquired a new stake in Cencora in the 3rd quarter valued at $1,404,000. Finally, HM Payson & Co. bought a new stake in Cencora during the 1st quarter valued at $708,000. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

NYSE COR opened at $249.70 on Monday. Cencora has a fifty-two week low of $195.83 and a fifty-two week high of $251.56. The stock has a market cap of $49.20 billion, a PE ratio of 33.08, a PEG ratio of 1.63 and a beta of 0.44. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. The firm’s fifty day moving average price is $233.56 and its two-hundred day moving average price is $232.01.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be given a $0.55 dividend. The ex-dividend date is Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.88%. Cencora’s dividend payout ratio (DPR) is 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.